These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 9212324)

  • 1. Role of amylin in nutrient intake - animal studies.
    Young A
    Diabet Med; 1997 Jun; 14 Suppl 2():S14-8. PubMed ID: 9212324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of glucagon secretion.
    Young A
    Adv Pharmacol; 2005; 52():151-71. PubMed ID: 16492545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roles of amylin in diabetes and in regulation of nutrient load.
    Young A; Denaro M
    Nutrition; 1998 Jun; 14(6):524-7. PubMed ID: 9646295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans?
    Asmar M; Bache M; Knop FK; Madsbad S; Holst JJ
    J Clin Endocrinol Metab; 2010 May; 95(5):2367-75. PubMed ID: 20194711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amylin receptor agonists: a novel pharmacological approach in the management of insulin-treated diabetes mellitus.
    Nyholm B; Brock B; Ørskov L; Schmitz O
    Expert Opin Investig Drugs; 2001 Sep; 10(9):1641-52. PubMed ID: 11772274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amylin and the gastrointestinal tract.
    Macdonald IA
    Diabet Med; 1997 Jun; 14 Suppl 2():S24-8. PubMed ID: 9212326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New treatments of diabetes: the beta-amylin agonists.
    Lebovitz HE
    Ann Endocrinol (Paris); 2008 Apr; 69(2):147-50. PubMed ID: 18423421
    [No Abstract]   [Full Text] [Related]  

  • 8. Inhibition of gastric emptying.
    Young A
    Adv Pharmacol; 2005; 52():99-121. PubMed ID: 16492543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Amylin--a partner hormone to insulin].
    Ascić-Buturović B; Surković I; Heljic B
    Med Arh; 2003; 57(3):177-8. PubMed ID: 12858660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pramlintide: A new tool in diabetes management.
    Want LL; Ratner RE
    Curr Diab Rep; 2006 Nov; 6(5):344-9. PubMed ID: 17076994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implications of amylin and amylin deficiency.
    Kruger DF; Gatcomb PM; Owen SK
    Diabetes Educ; 1999; 25(3):389-97; quiz 398. PubMed ID: 10531859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control.
    Weyer C; Maggs DG; Young AA; Kolterman OG
    Curr Pharm Des; 2001 Sep; 7(14):1353-73. PubMed ID: 11472273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of endogenous amylin in glucagon secretion and gastric emptying in rats demonstrated with the selective antagonist, AC187.
    Gedulin BR; Jodka CM; Herrmann K; Young AA
    Regul Pept; 2006 Dec; 137(3):121-7. PubMed ID: 16914214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Amylin--its physiological role in humans].
    Bronský J; Chada M; Kotaska K; Průsa R
    Cesk Fysiol; 2002 Dec; 51(4):176-80. PubMed ID: 12608111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effects of amylin and cholecystokinin on food intake and gastric emptying in rats.
    Reidelberger RD; Arnelo U; Granqvist L; Permert J
    Am J Physiol Regul Integr Comp Physiol; 2001 Mar; 280(3):R605-11. PubMed ID: 11171636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of amylin in insulin secretion and action in humans: antagonist studies across the spectrum of insulin sensitivity.
    Mather KJ; Paradisi G; Leaming R; Hook G; Steinberg HO; Fineberg N; Hanley R; Baron AD
    Diabetes Metab Res Rev; 2002; 18(2):118-26. PubMed ID: 11994903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing diabetes treatment using an amylin analogue.
    Edelman SV
    Diabetes Educ; 2008; 34 Suppl 1():4S-10S. PubMed ID: 18268000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of amylin and the amylin agonist pramlintide on glucose metabolism.
    Schmitz O; Nyholm B; Orskov L; Gravholt C; Møller N
    Diabet Med; 1997 Jun; 14 Suppl 2():S19-23. PubMed ID: 9212325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreatic amylin as a centrally acting satiating hormone.
    Lutz TA
    Curr Drug Targets; 2005 Mar; 6(2):181-9. PubMed ID: 15777188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Role of amylin in glucose homeostasis and its perspective use in diabetes management].
    Otto-Buczkowska E; Mazur-Dworzecka U; Dworzecki T
    Przegl Lek; 2008; 65(3):135-9. PubMed ID: 18624122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.